What's behind Alnylam Pharmaceuticals' latest 3.1% stock surge?

Traders Union
All News
Stocks
Alnylam pharmaceuticals rises 3.07% today

Highlights

Alnylam Pharmaceuticals received FDA approval for vutrisiran in the treatment of ATTR-CM, extending its label beyond polyneuropathy.
Shares of Alnylam Pharmaceuticals declined approximately 28% after second quarter results, and a law firm launched an inquiry into possible securities violations involving management.
Technical indicators show bearish momentum and weak trend strength, with the five-day expected price range at $225.32 to $247.34.

Institutional buying and legal scrutiny as label expansion meets past losses

Alnylam Pharmaceuticals received FDA approval for vutrisiran (Amvuttra) for the treatment of cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adult patients, expanding the label beyond its previous approval for polyneuropathy. On July 30, 2026, the company reported its second quarter results, after which shares declined by approximately 28%. Several institutions, including Wealthfront Advisers LLC, Mitsubishi UFJ Asset Management Co. Ltd., and Silvant Capital Management LLC, have initiated new positions in the company during the quarter. A law firm has also begun an inquiry into possible securities laws violations or other business practices involving Alnylam Pharmaceuticals and its senior management.

Anton Kharitonov, expert at Traders Union, takes a cautious stance despite Alnylam’s FDA approval. He notes the price bounce failed to regain key technical levels, with the stock remaining under both its 50-day and 200-day moving averages. Recent institutional interest is outweighed by a sharp 28% post-earnings drop and a law firm’s investigation into management practices. Kharitonov stresses that persistent downside pressure and legal uncertainties could limit any near-term recovery. He states, "Traders should treat any rebounds with skepticism until the stock reclaims $267.75 decisively and legal risks are clarified."

Viktoras Karapetjanc, expert at Traders Union, sees meaningful opportunity for Alnylam on the back of its expanded FDA approval. He highlights new institutional inflows as reinforcing robust long-term interest despite recent volatility. Karapetjanc believes the latest label expansion for vutrisiran opens a larger addressable market for the company, improving its fundamental outlook. He emphasizes, "I view the FDA decision and institutional buying as critical tailwinds, and I expect further growth as positive news flow persists."

Parshwa Turakhiya, analyst, spots a short-term technical rebound but notes that momentum is fragile. He observes that trading above the 20-day moving average brings limited bullish sentiment, yet major resistance at $238.91 still caps upside moves. Turakhiya warns that high downside probability persists, so traders should remain tactically flexible. He concludes, "Momentum traders might play quick rallies toward resistance, but I would not ignore the strong risk of renewed pressure below $234.13."

Short-term strength faces resistance as bearish structure dominates

ALNY is trading above its 20-day moving average ($234.13), but remains below the 50-day ($267.75) and 200-day ($332.01) averages. This setup points to short-term bullish interest overshadowed by persistent medium- and long-term selling pressure. The nearest resistance stands at $238.91, with the 20-day moving average offering support at $234.13. The Ichimoku Kijun level at $244.21 acts as another resistance, while the longer-term moving averages reinforce the broader bearish alignment.

Earlier, analysts noted that Alnylam Pharmaceuticals was experiencing persistent bearish technical momentum despite periodic rebounds. The latest FDA approval provides a fresh catalyst, but with downside momentum still dominant, the key level to monitor is support at $234.13, as a break below could signal further risk toward the $225.32 area.

Source of Data: ALNY Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.